drugset / Trial / NCT00708604

Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes

NCT00708604 ↗

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety of islet transplantation in patients with type 1 diabetes who have had a successful kidney transplant and have been maintained for at least three months on anti-rejection medications consisting of any combination of sirolimus, tacrolimus, MMF or prednisone (5 mg/day or less). Another purpose is to determine the effectiveness of an islet transplant in inducing insulin independence and whether or not an islet transplant improves quality of life for kidney transplants patients with type 1 diabetes.

Timeline

Start
2008-10-18
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Islet cell transplantation Cell therapy — Other